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Evaluation of the acute and subchronic oral toxicity of ethanol extract from
Valeriana pavonii  species in W ist ar rat s*
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SUMMARY
Introduction: One of the most frequent problems found in medicinal plants is the absence of clinical, toxicological, and
pharmacological studies. Valeriana pavonii s one of the species used in Colombia as an anxiolytic.  Further study of this
specie is rendered to add information in the toxicological area.
Objective: The acute and subchronic oral toxicity of V. pavonii ethanolic extract was evaluated in Wistar rats of both sexes.
 Materials and methods: The rats were distributed into four groups: the control group received the vehicle (0.5 mL/100
g of corporal weight) and the other three groups received increasing levels of the dosage for 90 days to evaluate characteristics
like physical exam, laboratory test (blood chemistry and  haematology), and anatomopathological findings.
Results: This study reveals that there were no signs of toxicity, mortality, or significant alterations attributable to the
ethanolic extract of V. pavonii.
Conclusions: The Not Observed Adverse Effect Levels (NOAEL) of V. pavonii ethanolic extract were 2000 and 1000 mg/
kg of body weight for the acute and subchronic toxicity studies, respectively.
Keywords: Toxicity tests; LOAEL; Valerian; NOAEL; Anxiolytic; Medicinal plants.
Evaluación de la toxicidad oral aguda y sub-crónica del extracto etanólico de la especie Valeriana pavonii en ratas
Wistar
RESUMEN
Introducción: Uno de los problemas más frecuentes asociados con el uso de plantas medicinales es la ausencia de
evidencias farmacológicas, toxicológicas y clínicas. Valeriana pavonii es una de las especies más utilizadas popularmente
en Colombia con fines ansiolíticos. Es necesario avanzar en el estudio de esta especie para aportar información en el campo
toxicológico.
Objetivos: Evaluar la toxicidad oral aguda y sub-crónica del extracto etanólico de V. pavonii en ratas Wistar de ambos
sexos.
Materiales y métodos: En cada uno de los estudios se distribuyeron ratas en cuatro grupos; un grupo control que recibió
únicamente vehículo (0.5 ml/100 g de peso corporal) y tres grupos correspondientes a niveles crecientes de dosis, así: para
el estudio de toxicidad aguda se administraron en dosis única 20, 200 y 2000 mg/kg con un período de observación de 14 días
y para el de toxicidad sub-crónica, dosis diarias de 250, 500 y 1000 mg/kg durante 90 días. Se evaluaron los parámetros de examen
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físico, los exámenes de laboratorio (química sanguínea y
hematología) y el estudio anatomopatológico.
Resultados: No se presentaron signos de toxicidad,
letalidad ni alteraciones significativas atribuibles al consumo
del extracto etanólico de V. pavonii, según el examen físico,
el examen anatomopatológico y el análisis de las pruebas de
química sanguínea y hematología.
Conclusiones: Los valores de nivel sin efectos adversos
observados (NOAEL) del extracto etanólico de V. pavonii,
fueron 2000 y 1000 mg/kg de peso corporal para los estudios
de toxicidad aguda y sub-crónica, respectivamente. No se
encontraron valores de nivel más bajo de efecto adverso
observado (LOAEL).
Palabras clave: Pruebas de toxicidad; LOAEL;
Valeriana; NOAEL; Ansiolítico; Plantas medicinales.
The use of medicinal plants has rapidly expanded
throughout the world1. Although there are no accurate
data to assess the global use of medicinal plants, the World
Health Organization (WHO) has estimated that over
80% of the world’s population uses traditional medicine
routinely as their source of primary health care. Frequently,
traditional treatments involve the use of plant extracts or
their active principles2. The quantity and quality of data on
safety and efficacy in traditional medicine, including
medicinal plants, are not enough to satisfy the necessary
criteria to support their use in the world3.
One of the main problems found in the field of
medicinal plants is the lack of pharmacological, toxico-
logical and clinical evidence. In many cases, this practice
is commonly associated with their traditional use4. Only
a small fraction among thousands of medicinal plants
used in the world has been rigorously tested in controlled
studies; therefore, the evidence of toxicity risks is even
lower5.
Valeriana is one of the genera of plants used as a
sedative to treat anxiety. However, their species show
important differences regarding their chemical compo-
sition V. pavonii is a species widely used in Colombia,
which contains 0.44% of alkaloid metabolites, whereas
V. officinalis contains less than 0.10% of these kinds of
compounds6.
There is a large trade in species of the genus Vale-
riana, not only as phytotherapeutic product but also as
fresh material in marketplaces. In Colombia, both species
are sold interchangeably, although their morphological
differences are notable7. V. pavonii, a native Colombian
species approved for sedative purposes, has the same
indications of V. officinalis8, which is one of the best
known and studied European species. However, unlike
the latter, V. pavonii lacks toxicological studies9. In this
research, the acute and subchronic toxicity of the
ethanol extract of V. pavonii was evaluated in Wistar
rats for 90 days. Part of the acute toxicity study was
presented at the XI Congreso Nacional de Farmacología
y Terapéutica.
MATERIALS AND METHODS
Ethanol extract. Fresh plant material was collected
in San Antonio del Tequendama (Cundinamarca, Co-
lombia), located at 2,500 m above sea level in the
Cordillera Oriental (one of the three main Colombian
mountain ranges) in October 2006. Two specimens
were classified and deposited in the Colombian National
Herbarium and were identified with the following codes:
495179 and 495756. Aerial parts of the plants were dried
in a forced-air oven at 40°C for 48 hours and pulverized
in a disc mill. The powder obtained was subjected to
percolation with 96% ethanol. The solvent was removed
by rotary evaporation at reduced pressure with an
average temperature of 40°C. Finally, the material was
dried at room temperature in a vacuum desiccator
protected from light. The vehicle used for dilution of the
ethanol extract was obtained from the mixture of 10%
propylene glycol, 10% glycerol, 1% polysorbate-80 and
distilled water in sufficient quantity to make up 100%.
Animals. Two groups of 60 Wistar rats per sex
( even to nine weeks old), weighing between 140-202 g
(females) and 180-270 g (males), provided by the
Department of Pharmacy, Faculty of Science, at Uni-
versidad Nacional were used for the two toxicity studies.
The animals were kept a room temperature, 22 ± 1°C,
and 12-hour light-dark cycles were provided. Feed and
water were given ad libitum.
Toxicity studies. This study was designed based on
the recommendations by the World Health Organization
(WHO). We took into account the guidelines for
assessing the toxicity of herbal medicines presented in
its «General guidelines for methodologies on research
and evaluation of traditional medicine» because they are
suitable for medicinal plant products. Recommendations
were followed in terms of number and sex of animals
used.
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Acute toxicity. Forty rats were used and divided
randomly into four treatment groups of 10 animals each
(five females and five males). The control group received
the vehicle (0.5 ml/100 g body weight) and the other
three groups corresponding to three dosage levels: 20,
200, and 2000 mg/kg. The extract or vehicle was admi-
nistrated by oral gavage in a single dose.
Subchronic toxicity. Eighty rats were randomly
assigned into four groups with 20 animals each (10
males and 10 females). The control group received the
vehicle (0.5 ml/100 g body weight) and the other three
groups received three dosage levels: 250, 500, and 1000
mg/kg. The extract or vehicle was administered daily by
oral gavage during 90 days.
Parameters evaluated in toxicity studies
Physical examination. The rats were observed
daily for two weeks throughout the acute toxicity study,
and for 90 days in the sub-chronic toxicity study.
Mortality was recorded and the presence, absence,
increase, or decrease of the following signs were com-
pared with the basal condition:
In the central nervous system (CNS): motor activity,
ataxia, analgesia, anesthesia, righting reflex, corneal
reflex, pineal reflex, paralysis of paw, grasping activity,
alarm reaction, tremors, head twitches, and convulsions.
In the eyes: enophthalmos, exophthalmos, ptosis, myosis,
mydriasis, nystagmus, lacrimation, chromodacryorrhea,
relaxation of the nictitating membrane, and corneal
opacity. In skin appearance: paleness, cyanosis, and
hyperemia. In general signs: salivation, piloerection,
erection of the tail (Straub tail), diarrhea, priapism,
dehydration (Robichaud test), dyspnea, and nasal
discharge. And «other signs»: passivity, aggressiveness,
fear, and respiratory rate10. Body weight was recorded
at the beginning and weekly thereafter in both studies.
Laboratory tests. At the end of the acute and sub-
chronic toxicity studies, all animals were anesthetized
with ether and the blood was collected from the abdo-
minal aorta. Blood samples were collected in two tubes
(one with EDTA) for determination of clinical chemistry
tests [blood urea nitrogen (BUN), creatinine, alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), bilirubin, sodium, glucose, amylase), and hema-
tology (erythrocyte count, total and differential leukocyte
count, platelet count, hemoglobin, hematocrit, and
sedimentation rate]. These samples were processed in
a clinical laboratory certified in the Quality Manage-
ment System (QMS) according  to ISO 9001. The
sacrifice of animals was performed under anesthesia by
exsanguinations after puncture of the aorta.
Pathology. All animals were subjected to necropsy
at the end of the toxicity studies, or earlier in case of
death. For histopathology, samples were taken from the
CNS, heart, lung, liver, kidney, spleen, pancreas, and
gastrointestinal tract and preserved in 10% buffered
formaldehyde. The tissues were processed by routine
technique for hematoxylin-eosin and, in some cases to
confirm the presence of iron pigment, Perl’s stain was
used. Macro and micro procedures were carried out at
the Pathology Laboratory, Faculty of Veterinary Medi-
cine, Universidad Nacional. The lesions observed were
classified as mild, moderate, or severe.
Statistical analysis. Longitudinal data-analysis with
dichotomous outcome variables (generalized estimating
equations, GEE) were used for physical examination
data in which positive cases were analyzed with respect
to total11. The blood parameters were processed by a
factorial analysis of variance (ANOVA) followed by
the Tukey test to determine the treatments responsible
for the significant differences. When variance was not
homogeneous, the Kruskal-Wallis test was applied.
Analysis of the pathological data was accomplished by
u ing Chi-square test in which categories such as
normal, mild, moderate, and severe were defined.  The
programs: Excel®, SPSS®16, and Stata®9 were used.
The criteria for statistical significance was p<0.05 in all
cases.
Ethical considerations. This study was evaluated
and approved in a meeting held on March 23, 2006 (Act
No. 05) by the Faculty of Medicine Ethics Committee,
at Universidad Nacional in Bogotá, DC, Colombia.
RESULTS
Acute toxicity
Physical examination. It was observed that no
deaths or signs of toxicity occurred during the assay.
Signs of passivity (10 rats) and piloerection (eight rats)
w re reported. The results were expressed as number
of positive observed cases (presence of the sign), taking
into account that the total number of cases in each para-
meter was 560. Significant differences in passivity (in
sex and time) and piloerection (in time) parameters
were observed. Passivity was higher in males (26 males
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and microscopic changes in any of the treatment groups
(Figures 1a and 1b).
Subchronic toxicity
Physical examination. Significant differences bet-
ween the treated and control groups were observed in
the following parameters: passivity (42), piloerection
(8), loss of alarm reaction (11), aggressiveness (16),
nasal discharge (21), dyspnea (18), and fear (25) in a
total of 80 rats.
Passivity showed significant differences in time,
dosage, and sex. This parameter was higher in the high
dosage group of males and during the last two weeks.
Significant differences were observed in time and dosage
Table 1
Effect of V. pavonii  ethanol extract on the weight of Wistar rats during the acute study
    Dose                                Females                                                       Males
  (mg/kg)        Initial weight       1st week 2nd week Initial weight 1st week 2nd week
High (2000) 183.9±9.8* 177.9±4.6 191.8±6 230.9±26.1 217.2±32.6 249.8±24.5
Mean (200) 181.8±18 186.4±15.1 195.7±10.3 210.9±21.2 219.3±20 240.0±17.4
Low  (20) 181.4±15 185.1±15.4 195.6±13.2 239.6±15.6 246.1±16.2 262.6±15.4
Control 178.4±13.9 183.4±15 193.5±16.9 220.9±6.7 229.5±17.1 258.6±12.3
* x + ems
and one female) during the two first days, while pilo-
erection appeared during the last three days. No significant
differences were observed in body-weight gain between
treated and control groups (Table 1).
Clinical chemistry. Female rats in the highest dosage
group showed significant differences of serum sodium
(decreased) and AST (increased) levels. The direct
bilirubin increased significantly in the highest dosage
group in both females and males (Table 2).
Hematology. There were no significant differences
in hematological parameters between treated and con-
trol groups (Table 3).
Pathology. There were no significant macroscopic
Table 2
Blood chemistry values in Wistar rats 14 days after administration in single oral dosage
of V. pavonii  ethanol extract
  Parameters    Females         Males
                     Low dose     Mean dose     High dose       Control    Low dose   Mean dose    High dose    Control
             (20)1                (200)               (2000)                                 (20)*                 (200)               (2000)
Glucose (mg/dl) 201.8 ±6.22 177.6 ±32.5 177.8 ±34.8 165.6 ±18.3 131.8 ±20.3 170.2 ±36.7 195.4 ±34.9 200.0 ±24.8
Creatinine (mg/dl) 0.88 ±0.18 0.70 ±0.06 0.68 ±0.04 0.62 ±0.02 0.62 ±0.18 0.50 ±0.04 0.80 ±0.08 0.54 ±0.06
BUN (mg/dl) 37.9 ±3.5 34.0 ±4.1 33.7 ±1.5 34.4 ±2.5 23.3 ±3.6 25.7 ±3.1 30.5 ±3.2 29.4 ±3.9
ALT U/l 44.8 ±7.9 43.6 ±6.4 61.0 ±4.7 34.8 ±7.1 36.2 ±8.5 55.6 ±19.3 43.0 ±12.3 55.0 ±4.7
AST U/l 99.8 ±6.8 118.6 ±20.0 204.8±2063 128.8 ±11.1 150.4 ±29.1 182.2 ±24.9 121.8 ±33.3 145.0 ±35.3
Total bilirubin
   (mg/dl) 0.92 ±0.06 1.20 ±0.26 1.62 ±0.42 0.94 ±0.08 0.96 ±0.13 0.84 ±0.08 1.48 ±0.20 0.98 ±0.10
Direct bilirubin
   (mg/dl) 0.50 ±0.05 0.58 ±0.07 0.96 ±0.222 0.42 ±0.07 0.42 ±0.10 0.40 ±0.06 0.73 ±0.132 0.42 ±0.08
Sodium (mEq/l) 135.1 ±3.9 138.1 ±6.8 110.8 ±3.82 135.7 ±4.3 131.4 ±3.2 140.1 ±4.2 139.8 ±7.3 135.6 ±5.3
Amylase (U/l) 689.6±113.9 612.0 ±85.2 721.0±144.8 497.6±124.3 578.3±213.1 627.7±232.0 792.0 ±88.5 744.5±131.1
1.  mg/kg    2. x ± ems    3. Significant difference with respect control group (p<0.05)
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for loss of alarm reaction (increased during the study in
the low dosage group). Aggressiveness was higher in
the control group and between the second and seventh
weeks. Nasal discharge increased in the highest dosage
group and from the fifth week until the end of the study.
Dyspnea presented differences in time and sex. This
parameter was higher during the last two weeks and in
males. Significant differences were observed throughout
time for piloerection (during the first three weeks) and
fear (higher during the first four weeks) (Table 4). No
significant differences in body weight gain were observed
between the treated and control groups (Table 5).
Clinical chemistry. Significant differences between
females and males were observed for blood urea nitrogen
(higher in females), glucose (higher in males) and direct
bilirubin (lower in males) (Table 6).
Hematology. The erythrocyte count was significantly
reduced in the high dosage group of females and males.




Hematology values in Wistar rats 14 days after administration in single oral dosage of
V. pavonii  ethanol extract
                      Females           Males
                     Low dose     Mean dose     High dose       Control    Low dose   Mean dose    High dose    Control
             (20)1                (200)               (2000)                                 (20)*                 (200)               (2000)
Leukocyte 4.7±0.5* 6.0 ±0.7 4.0 ±0.4 5.2 ±0.2 5.0 ±0.6 6.3 ±0.8 5.3 ±0.6 8.5 ±0.9
(thousands/mm3)
Erythrocyte 6.79±0.16 6.20 ±0.62 5.97 ±0.47 6.80 ±0.21 7.07 ±0.27 7.15 ±0.29 6.81 ±0.42 6.24 ±0.92
(million/mm3)
Hemoglobin (g%) 14.7±0.3 13.6 ±1.0 13.4 ±0.3 14.6 ±0.3 15.0 ±0.6 15.3 ±0.5 14.8 ±0.8 13.4 ±2.0
Hematocrit (%) 41.5±1.1 37.4 ±3.6 35.2 ±2.8 40.7 ±1.1 42.3 ±2.0 43.1 ±1.6 41.2 ±2.7 38.1 ±5.6
Platelet count 355±134 295 ±104 557 ±168 389 ±100 555 ±123 436 ±119 388 ±51 277 ±67
(thousands/mm3)
Eritrosedimentation 0.2±0.2 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0
rate (mm/1h)
Differential leukocyte
Lymphocyte (%) 94.1±1.6 89.3 ±2.8 91.6 ±2.1 91.8 ±1.8 89.7 ±3.2 91.0 ±3.0 86.3 ±3.1 91.6 ±2.1
Granulocyte 3.7±1.7 9.1 ±3.3 4.6 ±2.2 5.3 ±2.4 8.9 ±3.9 5.3 ±3.8 11.7 ±4.1 4.0 ±2.7
(neut, %)
* x ± ems
Table 4
Physical examination parameters that showed differences in gender or in dosage during
subchronic toxicity study of V. pavonii  ethanol extract
Parameter        Total positive cases 1                     Dose (mg/kg)                                Sex
                                          Low 20    Mean 200  High 2000    Control  Females   Males
Passivity 144 212 442 762 3 293 1153
Loss of alarm reaction 20 92 5 4 2 12 8
Aggressiveness 21 42 22 22 13 7 14
Nasal discharge 27 4 5 152 3 10 17
Dyspnea 35 2 16 17 0 113 243
1. Total cases observed: 944   2. Significant difference with control group (p<0.05)   3. Significant difference between sexes (p<0.05).
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Table 6
Clinical chemistry values in Wistar rats after oral administration of V. pavonii  ethanol
extract for 90 days
Parameters                                Females (dose mg/kg)                                                     Males (dose mg/kg)
            Low dose 250  Mean dose 500  High dose 1000  Control    Low dose 250   Mean dose 500 High dose 1000   Control
Glucose 107.1±6.61,2 108.0 ±9.31 100.5 ±6.41 110.2±10.51 163.8±11.91 153.4±11.81 138.6±14.11 162.0±16.01
(mg/dl)
Creatinine 0.81 ±0.05 0.87 ±0.08 0.89 ±0.05 0.79 ±0.07 0.74 ±0.02 0.72 ±0.03 0.74 ±0.03 0.81 ±0.08
(mg/dl)
BUN (mg/dl) 24.6 ±2.0* 24.5 ±2.61 25.0 ±1.91 22.1 ±1.81 18.2 ±1.11 19.4 ±0.91 20.4 ±1.01 21.0 ±1.21
ALT U/ 34.3 ±3.7 42.5 ±6.9 28.8 ±3.4 36.8 ±4.4 46.1 ±8.1 38.8 ±4.5 33.0 ±2.1 48.3 ±5.4
AST U/l 139.0 ±13.3 207.9 ±28.8 170.5 ±28.4 148.9 ±12.7 182.0 ±22.4 182.8 ±15.4 160.5 ±12.4 185.7 ±20.0
Total bilirubin 0.91 ±0.22 1.01 ±0.23 1.03 ±0.12 0.83 ±0.09 0.73 ±0.07 0.71 ±0.05 0.59 ±0.04 0.75 ±0.13
(mg/dl)
Direct bilirubin 0.51 ±0.171 0.53 ±0.141 0.52 ±0.081 0.44 ±0.061 0.27 ±0.071 0.28 ±0.051 0.21 ±0.041 0.30 ±0.081
(mg/dl)
Indirect bilirubin 0.41 ±0.07 0.48 ±0.09 0.52 ±0.05 0.39 ±0.05 0.46 ±0.05 0.43 ±0.04 0.38 ±0.03 0.45 ±0.07
(mg/dl)
Sodium 139.0 ±1.5144.1 ±2.9 143.1 ±3.1 145.5 ±2.2 138.6 ±2.2 139.0 ±1.2 142.0 ±3.4 139.8 ±1.6
(mEq/l)
Amylase 260.8 ±21.5 222.0 ±15.3 246.9 ±13.9 240.7 ±14.4 298.3 ±19.3 322.0 ±34.5 331.3 ±32.1 323.8 ±34.9
(U/dl)
1. Significant difference between sexes (p<0.05)     2. x ± ems
Table 5
Effect of V. pavonii  ethanol extract on the weight of Wistar rats during the subchronic study
eek Males Females
Week                                 Males (dose mg/kg)                                                            Females (dose mg/kg)
High dose 1000    Mean dose  500  Low dose 250 Control      High dose 1000 Mean dose  500 Low dose 250     Control
High dose 1000 mg/kg Mean dose    500 mg/kg Low dose 250 mg/kg Control High dose
0 231.7±13.1* 226.3±6.2 223.3±10.3 225.9±8.4 174.7±6.2 178.2±5.5 179.2±5.3 174.6±6.6
1 237.1±16.5 231.3±8.7 234.9±11.2 236.8±9.4 176.8±6.0 183.4±5.8 182.1±4.5 177.6±6.3
2 241.6±16.1 232.5±8.3 241.7±10.7 246.6±9.3 185.3±4.7 191.1±6.6 190.3±5.4 189.5±5.7
3 256.8±19.9 242.2±9.7 254.4±11.1 260.0±10.4 189.7±3.8 200.3±8.4 198.1±4.4 194.9±6.7
4 268.1±16.1 257.0±9.8 270.7±10.8 272.3±11.1 194.4±3.5 207.4±8.2 202.0±4.1 203.3±5.3
5 276.7±15.1 262.4±9.1 275.7±10.3 284.6±13.7 199.8±4.4 212.0±7.2 205.7±5.0 208.4±4.9
6 287.2±14.9 272.2±9.2 285.9±10.3 285.4±10.8 202.4±5.0 216.6±7.8 209.5±4.9 206.5±7.3
7 293.6±15.2 279.8±8.7 293.2±10.3 290.1±10.3 203.3±5.2 221.6±9.2 215.1±6.3 207.7±7.2
8 304.1±16.1 290.5±9.3 301.8±11.6 297.7±9.9 207.0±5.0 228.6±9.6 219.1±6.4 211.9±7.5
9 313.7±17.1 296.2±9.3 309.7±12.0 305.4±10.0 208.1±5.0 231.0±10.1 221.2±6.4 214.8±7.3
10 320.2±17.2 300.4±9.5 313.0±11.9 312.6±9.8 211.1±4.9 233.8±10.1 223.1±6.9 217.1±7.6
11 327.9±18.5 305.6±9.7 319.3±13.1 322.8±10.1 213.8±4.9 236.8±10.0 226.3±7.0 219.2±7.9
12 330.3±16.9 308.7±9.6 325.8±14.1 327.5±10.4 212.7±5.2 236.7±11.2 224.7±6.9 219.0±8.0
13 331.1±16.2 314.3±10.5 329.9±15.1 329.4±10.8 220.4±5.7 236.2±12.2 224.0±3.1 216.3±6.2
* x ± ems
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Table 7
Hematology values in Wistar rats after oral administration of V. pavonii  ethanol extract for 90 days
Parameters                                Females (dose mg/kg)                                                     Males (dose mg/kg)
              Low dose 250  Mean dose 500  High dose 1000  Control     Low dose 250  Mean dose 500 High dose 1000  Control
Leukocyte 4.7±0.61 5.3 ±0.9 4.5 ±0.3 3.8 ±0.5 5.6 ±0.6 5.0 ±0.9 5.1 ±0.3 4.2 ±0.5
(thousands/mm3)
Erythrocyte 6.88 ±0.26 6.79 ±0.21 5.12±0.552 6.37 ±0.42 7.25 ±0.26 7.41 ±0.21 6.88±0.552 8.00 ±0.42
(million/mm3)
Hemoglobin 15.0 ±0.6 14.9 ±0.5 11.7 ±1.1 13.7 ±0.8 15.0 ±0.6 15.1 ±0.5 14.5 ±1.1 14.9 ±0.8
 (g%)
Hematocrit (%) 40.8 ±1.5 40.6 ±1.3 31.8 ±3.3 35.4 ±3.2 41.5 ±1.5 42.3 ±1.3 40.2 ±3.3 42.0 ±3.2
Platelet count 950.0 ±155.9 772.0 ±101.0 869.0 ±102.2 880.6 ±59.0 731.5 ±155.9 965.5 ±101.0 922.0 ±102.2 850.2 ±59
(thousands/mm3)
Eritrosedimen- 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0    rate
tation (mm/1h)
Differential leukocyte
Lymphocyte % 90.8 ±2.2 92.7 ±2.0 93.4 ±1.1 92.6 ±0.9 92.5 ±2.2 94.1 ±2.0 90.0 ±1.1 91.4 ±0.9
Granulocyte 5.4 ±2.7 4.4 ±2.2 1.9 ±0.7 4.1 ±1.2 3.0 ±2.7 3.4 ±2.2 6.1 ±0.7 4.9 ±1.2
(neut) %
1. x ± ems.  2. Significant difference with control group (p<0.05)
a b
Pathology. There were 13 deaths during the
subchronic study (eight rats within the first 16 days, one
rat on days 44, 48, and 86, respectively, and two rats on
day 90). The deaths occurred in a female rat from the
control group, and two females and two males from
each treated group. The mortality rate was low and
similar in all groups. At necropsy, tracheitis was observed
in all cases.
Depletion of T areas was seen in spleen (higher in the
lower dosage group) as the only significant finding
(Figures 2a y 2b). The following findings were not
significant: Kupffer cell activation, mild bile duct
hyperplasia, megalocytosis in the liver (Figures 2c-2f),
a d hemoglobin pigment in the spleen (hematoxylin-
eosin and Perl’s stain, Figures 2g and 2h).
DISCUSSION
The ethanol extract from Valeriana pavonii could
b  classified according to the Globally Harmonized
Classification System for Chemical Substances and
Mixtures (GHS)12 under the fifth category, taking into
Figure 1. a. Liver. Acute study, animal control. Note normal architecture: form of hepatocytes and
their nucleus. Staining H.E. 400X approx. b. Liver. Acute study, high-dosage animal. Note normal
architecture and morphology of hepatocytes. Staining H.E. 400X approx
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Figure 2. a. Spleen. Sub-
chronic study. Animal con-
trol. Lymphoid follicle is
seen at the germinal center
B (B) and the marginal zone
or area T (T). Staining
H.E.100X approx. b. Spleen.
Subchronic study. Low-
dosage animal. Note the
depletion of the T areas (T)
compared with control. B
areas may also be depleted
(B). Staining H.E. 100X
approx. c. Liver. Subchronic
study. Animal control. Note
the normal architecture of
hepatocytes, their cyto-
plasm, nuclei and the nor-
mal population of Kupffer
cells (arrow); Staining HE
400X approx. d. Liver. Sub-
chronic study. High-dosage
animal. Note the increase
in the number of Kupffer
cells (arrows); Staining
HE400X approx. e. Liver.
Subchronic study. High-
dosage animal. Note bile
duct hyperplasia (arrows);
Staining HE200X approx. f.
Liver. Subchronic study.
High-dosage animal. There
are some enlarged nuclei
(arrows) compared with
normal (arrowhead). Stai-




are evident (arrows); Stai-
ning HE200X approx. h.
Spleen: subchronic study.
High-dosage animal. Perl’s
staining for iron confirmed
that spleen pigments are
iron pigment derived from
hemoglobin. (Arrows). Iron.
Perl’s stain 200X approx.
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account that  he administration of this extract in a single
2000-mg/kg dose produced no deaths or signs of toxicity.
While the acute and subchronic toxicity studies revealed
no weight loss of the rodents. This finding was important
because if an animal were to have lost weight, it would
have been indicative of an illness process 13.
In these studies, passivity seems to respond to
sedative effects of V. pavonii, which have been
previously evaluated6. These effects have already been
reported for other Valeriana species, e.g., V.
officinalis14,15. This parameter was marked in the
subchronic toxicity study in which a dosage-response
relationship was observed.
Throughout the acute study, it was observed that
piloerection augmented slightly with time. This reaction
could be because of the animal’s level of stress increasing
due to the loss of the V. pavonii sedative effects
considering that the administration was done in a single
dosage16. In the subchronic study, this reaction appeared
during the first three weeks and it could be attributed to
the stress produced by the daily gavage administration.
This effect decreased gradually as a result of habituation
and, possibly the anxiolytic effect of the extract6.
Aggressiveness and fear decreased over time because
the degree of distress caused by the procedures was
minimized given that animals are creatures of habit17.
Although rats are not typically aggressive13, they showed
a dosage-response effect with the administration of V.
pavonii, suggesting that this species exerts sedative/
anxiolytic effects6.
The alarm reaction decreased over time. This seems
to be related to the sedative effects of V. pavonii found
in other species such as V. officinalis14,15. The sedative
action of Valeriana has been attributed to the presence
of several compounds like iridoids (valepotriates),
decomposition products (baldrinals), and various
components of the essential oil; particularly, the valerenic
acid derivatives15.  Furthermore, nasal discharge and
dyspnea can be attributed to complications associated
with gavage administration such as aspiration and airway
injury16.
In the acute toxicity test, female rats showed
statistically significant increases in serum AST levels,
but there were no histopathological findings.  Moreover,
AST is not specific to liver function in rats and has low
diagnostic value in this species13.  The mild hyponatremia
could be due to a mild hypotonic dehydration, while the
direct bilirubin increase could be because it was not
removed quickly from the serum and it could lead to its
accumulation. Therefore, this finding will become
significant if it is accompanied by total hyperbilirubinemia,
physical findings, and results from other laboratory
tests18.
The decrease in erythrocyte count in the high-
dosage group was compared with the hemoglobin and
hematocrit normal values, suggesting anemia by
hemodilution.  This effect is frequently observed at high
doses in toxicology studies with rats and it is generally
considered to lack toxicological significance16.
Females and males presented differences in BUN,
ALT, and AST serum levels. This could be due to
variability associated with gender, strain, age, site of
collection, anesthetic agents, among others13,16,19.
Because of all these variations, it is important to compa-
r  with control groups from each study and include both
genders in the study16,20.
In the histopathological study, the depletion of T
areas in the spleen could not be attributed to the extract
si ce this is a nonspecific reaction to stress, immune-
suppression or to agonal changes21.
Kupffer cells located in the liver are targeted by toxic
agents. They are not uncommon in toxicology studies
and they show high variability16 but they are not considered
as specific findings of toxicity. In bile ducts, slight
hyperplasia may be physiological due to the increase in
metabolic demand caused by the daily administration of
a xenobiotic22.
Megalocytosis is commonly found in rats under
physiological conditions. Moreover, in this study there
were no alterations in liver enzyme levels and there
were no other histopathological findings; hence, it could
not be considered a finding of specific toxicity. The
presence of pigments derived from hemoglobin in the
spleen was normal, considering that many of the red
blood cells destroyed were phagocytosed by reticulo-
endothelial cells23.
No relationship was found between the altered
values of clinical chemistry (AST, sodium, direct bilirubin)
and hematology (erythrocyte count), with histopatho-
logical findings.  In addition, most lesions in the pathology
and alterations in the blood parameters were presented
in both treated and control groups. The deaths that
occurred during the study were related to gastric gavage
manipulation, leading first to fibrino-suppurative tracheitis
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and then death.
Although there were no signs of acute and subchronic
toxicity attributable to the ethanolic extract of Valeriana
pavonii, in V. officinalis, hepatotoxic reactions have
been reported with valerian products; these reactions
could be idiosyncratic14,24. There is no reported data on
toxicity for long-term use of Valeriana. Toxicological
studies have reported for the ethanol extract of V.
officinalis an intraperitoneal LD50 of 3.3 mg/kg in
rats14, while the LD50 for this study was higher than
2000 mg/kg.  These values are not comparable because
the route of administration was different.  Through in
vitro studies, it has been demonstrated that valepotriates
(valtrate and didrovaltrate) have significant cytotoxic
and mutagenic activity.  However, toxicity was not
demonstrated in vivo or in human clinical trials25.
Therefore, it is important to complement this study with
toxicity tests in vivo and in vitro to discard cytotoxicity
and mutagenicity effects, keeping in mind that iridoids
have been found in this species.
In conclusion, in acute and subchronic toxicity studies
we did not observe mortality or signs of toxicity
attributable to the administration of ethanol extract from
V. pavonii and no significant weight loss was registered.
Therefore, the NOAEL  for the acute toxicity study was
2000 mg/kg and for the subchronic toxicity study was
1000 mg/kg weight. According to the dosage levels
evaluated in the subchronic and acute toxicity studies,
the LOAEL (Lowest Observed Adverse Effect Level)
was not found for the V. pavonii ethanol extract.
Conflict of interest. None of the authors has conflicts
of interest related to this study.
ACKNOWLEDGEMENTS
This study was funded by the Research Direction of
the Bogotá campus, Research Vice-Presidency of
Universidad Nacional de Colombia (Project DIB code:
8009046). The authors would like to thank the
Department of Pharmacy, the Faculty of Sciences, and
the Department of Toxicology, Faculty of Medicine,
Universidad Nacional de Colombia.
REFERENCES
1. World Health Organization. WHO guidelines on safety
monitoring of herbal medicines in pharmacovigilance systems.
Geneva: WHO; 2004.
2. Bermúdez A, Oliveira-Miranda MA, Velázquez D. La inves-
tigación etnobotánica sobre plantas medicinales: Una revisión
de sus objetivos y enfoques actuales. Interciencia. 2005; 30:
453-9.
3. Organización Mundial de la Salud. Estrategia de la OMS sobre
medicina tradicional 2002-2005. Ginebra: OMS; 2002.
4. Beyra A, León MC, Iglesias E, Ferrándiz D, Herrera R, Volpato
G, et al.  Estudios etnobotánicos sobre plantas medicinales en
la provincia de Camagüey (Cuba). An Jard Bot Madr. 2004; 61:
185-204.
5. De Smet PA. Herbal remedies. N Engl J Med. 2002; 347: 2046-
56.
6. Celis CT, Rincón J, Guerrero MF.  Actividad farmacológica
sobre el sistema nervioso central del extracto etanólico y de la
fracción alcaloidal de V. pavonii. Rev Colomb Cien Quim Farm.
2007; 36: 11-22.
7. Giraldo SE, Rincón J, Puebla P, Marder M, Wasowski C, Vergel
N, et al. Isovaleramida: principio anticonvulsivante aislado de
Valeriana pavonii. Biomedica. 2010; 30: 245-50.
8. Ministerio de la Protección Social, Instituto Nacional de Me-
dicamentos y Alimentos. Normas farmacológicas 2006. Bo-
gotá, DC: Ministerio de la Protección Social; 2006.
9. Ministerio de la Protección Social. Vademecum colombiano de
plantas medicinales 2008. Bogotá, DC: Ministerio de la Pro-
tección Social; 2008.
10. Moser VC, Cheek BM, McPhail RC. A multidisciplinary
approach to toxicological screening: III. Neurobehavioral
toxicity. J Toxicol Environ Health A. 1995; 45: 173-210.
11. Twish JWR. Applied longitudinal data analisis for epidemiology:
a practical guide. New York: Cambridge University Press;
2005.
12. Naciones Unidas. Sistema global armonizado de clasificación
y etiquetado de productos químicos (SGA). Parte 3, Peligros
para la salud. 2ª ed. Ginebra: Naciones Unidas; 2007. p. 115.
13. Suckow M, La Regina M, Sharp P. The laboratory rat. Boca
Raton: CRC Press; 2000.
14. Barnes J, Anderson L, Phillipson J. Plantas medicinales.
Barcelona: Pharma Editores; 2004.
15. Marder M. Viola H, Wasowski C, Fernández S, Medina JH,
Paladín AC. 6-methylapigenina and hesperidin: new valeriana
flavonoids with activity on the CNS. Pharmacol Biochem
Behav. 2003; 75: 537-45.
16. Suckow M., Weisbroth S, Franklin C. The laboratory rat. 2nd
ed. London: Elsevier Academic Press; 2006.
17. Bennett BT, Brown MJ, Schofield JC. Essentials for animal
research a primer for research personnel. Chapter 2, Alternative
methodologies. p. 9. 2nd ed. Maryland: USDA; 1994. [fecha de
acceso 7 de mayo de 2006]. URL disponible en: http://
www.nal.usda.gov/awic/pubs/noawicpubs/essentia.htm#2
18. Thrall M, Baker D, Lassen E, Campbell T, Rebar A, DeNicola
D, et al.  Veterinary hematology and clinical chemistry. Baltimore:
Lippincott Williams & Wilkins; 2004.
19. Reilly J. Variables in animal based research: Variability
associated with experimental conditions and techniques.
ANZCCART News. 1998; 11 Pt2: 1-7.
20. Petterino C, Argentino-Storino A. Clinical chemistry and
266
Colombia Médica                  Vol. 41 Nº 3, 2010 (Julio-Septiembre)
haematology historical data in control Sprague-Dawley rats
from pre-clinical toxicity studies. Exp Toxicol Pathol. 2006; 57:
213-19.
21. Greave P.  Histopathology of preclinical toxicity studies. 3rd ed.
London: Elsevier; 2007.
22. Grasso P.  Essentials of pathology for toxicologists. London:
Taylor & Francis; 2002.
23. Guyton A, Hall J. Tratado de fisiología médica. 10ª ed.  México:
McGraw-Hill Interamericana;  2001
24.  Stevinson C, Ernst E. Valerian for insomnia: a systematic
review of randomized clinical trials. Sleep Med. 2000; 1: 91-9.
25. Yao M, Ritchie H, Brown P.  A developmental toxicity-
screening test of valerian.  J Ethnopharmacol. 2007; 113: 204-
9.
